Inclusion Criteria:

- Participants must have premalignant lesions.

- Lesion sites include oral cavity, oropharynx, and larynx.

- Must have at least a >20 pack-year history of smoking.

- Must have a ECOG/Zubrod performance status of 0-1.

- Participants must be 18 years of age or older.

- No contraindications for laryngoscopy and biopsy.

- Adequate liver function.

- Must have hemoglobin and hematocrit levels at or above the lower limit of the normal
range.

- Participants must have PT/PTT levels at or above the lower limit of the normal range.

- Women of child-bearing potential must have a negative serum pregnancy test within 72
hours of receiving treatment.

- Must be able to swallow the oral dose of erlotinib and celecoxib.

- Participants must be disease free.

- Final eligibility will be determined by the health professionals conducting the
trial.

Exclusion Criteria:

- Participants with acute intercurrent illness or those who had surgery within the
preceding 4 weeks unless they have fully recovered.

- History of previous malignancies unless the cancer was stage I or II and rendered
free of disease more than 1 year.

- Pregnant or breast feeding.

- Not practicing adequate contraception if the participants are of child bearing
potential.

- Female patients who have a positive pregnancy test.

- History or recent myocardial infarction.

- Hypertension not adequately controlled by medication.

- Documented history of coagulopathy.

- Documented history of CHF greater than NYHA Grade II.

- Participants who were taking COX-2 inhibitors or EGFR tyrosine kinase inhibitors
within 3 months of study entry.

- Documented history or interstitial lung disease.

- Known connective tissue disease.

- History of NSAID-induced ulcers or those who are at risk for a GI ulcer.

- Participated in a clinical trial of an investigational drug within 12 months prior to
enrollment.

- Final eligibility will be determined by the health professionals conducting the
trial.